India’s copycat drugmakers gear up to offer cheaper weight-loss drugs
Expiry of Novo Nordisk’s UK patent for Saxenda seen as offering a ‘dry run’ for future generic versions of Ozempic
Read moreExpiry of Novo Nordisk’s UK patent for Saxenda seen as offering a ‘dry run’ for future generic versions of Ozempic
Read moreAccounting firm cites poor market for mergers and acquisitions and private equity activity
Read moreManufacturers must sell more electric cars to meet tough new EU carbon targets
Read moreWeak growth and reduced price pressures could force European Central Bank to consider prolonged series of rate cuts
Read moreTurning to ChatGPT stopped weeks of procrastination over an email
Read more